Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
29.23
-0.89 (-2.95%)
Mar 31, 2025, 9:47 AM EDT - Market open
Veracyte Revenue
In the year 2024, Veracyte had annual revenue of $445.76M with 23.46% growth. Veracyte had revenue of $118.63M in the quarter ending December 31, 2024, with 20.81% growth.
Revenue (ttm)
$445.76M
Revenue Growth
+23.46%
P/S Ratio
5.17
Revenue / Employee
$540,976
Employees
824
Market Cap
2.28B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 445.76M | 84.71M | 23.46% |
Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VCYT News
- 5 days ago - New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - Business Wire
- 11 days ago - Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 - Business Wire
- 4 weeks ago - Solid Growth, Soft Outlook: Why I'm Holding On Veracyte - Seeking Alpha
- 4 weeks ago - Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive - Benzinga
- 4 weeks ago - Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 5 weeks ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research - Business Wire